IV Insulin Therapy Developer Defends Diabetes Treatment Before CMS
This article was originally published in The Gray Sheet
Executive Summary
CMS should evaluate individually the various techniques it categorizes as outpatient intravenous insulin therapy before deciding which, if any, it will cover, say two commenters to the Medicare agency
You may also be interested in...
Outpatient IV Insulin Therapy Evidence Doesn't Warrant Coverage, CMS Says
Evidence supporting outpatient intravenous insulin therapy as an adjunctive diabetes treatment is insufficient to justify Medicare coverage, CMS says in a Sept. 25 proposed decision memo
CMS Exploring Coverage Of Outpatient Intravenous Insulin Treatments
Outpatient intravenous insulin treatment could gain traction as an adjunctive diabetes therapy under a CMS coverage analysis initiated March 25
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”